News | Radiation Therapy | May 19, 2016

Leeds Cancer Centre Acquires Eight Elekta Linear Accelerators

Versa HD linacs will allow more advanced forms of radiation therapy treatment, including stereotactic body radiation therapy and volumetric modulated arc therapy

Elekta, Versa HD linear accelerators, Leeds Cancer Centre U.K.

May 19, 2016 — Leeds Cancer Centre, one of the largest providers of cancer care in the U.K., will upgrade its existing treatment equipment with eight Elekta Versa HD linear accelerators.

Viv Cosgrove, Ph.D., head of radiotherapy physics at Leeds Cancer Centre, said, “The new linear accelerators are able to deliver improvements in treatment accuracy for patients. This will help us increase the use of high-dose radiation treatments such as stereotactic body radiotherapy. These treatments reduce the total number of patient visits whilst improving clinical effectiveness.

“The replacement of the existing equipment also allows us to create a very advanced platform for increasing our research and innovation programs, all of which directly benefit patients in the form of clinical trials and research initiatives.”

The Versa HD linear accelerators will include Agility multileaf collimators. These, combined with volumetric modulated arc therapy (VMAT) delivery, could enable clinicians at Leeds Cancer Centre to deliver complex head and neck plans up to 42 percent faster.

The deal was facilitated by Medipass, a leading European managed equipment services company, which partners with hospitals to manage efficient medical equipment solutions.

Seven of the eight linear accelerators were booked during the fourth quarter of Elekta’s fiscal year 2015-16.

For more information: www.elekta.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.